Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology, Inc. - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
FDA panel backs Puma's neratinib, clearing path to approval | Fierce Biotech
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Nerlynx (neratinib) Cancer Medication - Cancer Health
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
U.S. Food and Drug Administration Approves Puma's NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Earl
Puma Biotechnology
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
Nerlynx: Package Insert - Drugs.com
Neratinib (HKI-272) | HER2/EGFR Inhibitor | MedChemExpress
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
EX-99.1
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace
Puma's controversial cancer drug secures FDA approval - MedCity News
Marketing Application for Early Stage Breast Cancer Therapy Neratinib Submitted to EMA by Puma Biotechnology - Breast Cancer News
